Nanoflex Robotics AG has secured €12.5 million in blended financing from the prestigious European Innovation Council Accelerator, consisting of a €2.5 million grant and a €10 million equity investment. The company was one of only 38 businesses selected across Europe from a pool of approximately 1,000 applicants, making it one of just four Swiss companies chosen and the sole medical technology firm among them.
The funding will be used to complete clinical validation, secure European CE marking, and bring the first commercial version of its next-generation telerobotics platform to market.
Related: Lumitron closes USD $50 million investment for HyperVIEW platform
Spun out of ETH Zurich, Nanoflex Robotics develops electromagnetically controlled systems designed for endovascular interventions, with a primary focus on treating stroke. Unlike conventional, manually pushed rigid tools, this platform utilizes advanced magnetic navigation to steer ultra-flexible guidewires and catheters through complex blood vessels with superior speed, safety, and precision. Ultimately, this remote, teleoperated capability is designed to allow specialists to perform time-critical procedures from afar, effectively bridging the care gap between rural and urban communities.
“This funding is a major step toward expanding clinical validation of the Nanoflex Robotics platform, and a fantastic endorsement of our team, our technology, and the business we’re building. Our unique electromagnetically controlled robotic platform navigates blood vessels faster and more accurately than today’s devices. We are honored to have the EIC’s support — a powerful affirmation of our mission to close the gap in access to treatment between rural and urban communities.” said Matt Curran, CEO of Nanoflex Robotics.
